Methyl 2-(4-iodo-2-methylphenyl)-2-oxoacetate (i)
. Methyl 2-chloro-2-oxoacetate (323 µL, 3.510 mmol) was added to a solution of 3-iodotoluene (300 µL, 511.2 mg, 2.340 mmol) in anhydrous CH2Cl2 (5 mL). The mixture was stirred for 10 min and then cooled to −30ºC followed by the addition of AlCl3 (1.2 g, 9.015 mmol) in small portions (in about 10 min). The mixture was stirred at the same temperature for 90 min, during which the color changes to dark red. The reaction mixture was poured into a mixture of crushed ice and conc. HCl and extruded with CH2Cl2. The combined organics layers were washed successively with a 10% aqueous solution of Na2S2O3, a 0.1 M solution of NaOH and brine, dried over anhydrous Na2SO4 and concentrated to give a residue that was purified by chromatography, using hexane-Et2O (9:1) as eluent, to afford, in order of elution, title compound i (348,6 mg, 49%), as a white solid, followed by methyl 2-oxo-2-(m-tolyl)acetate (92.4 mg, 13%), as a colorless oil, and regioisomeric methyl 2-(2-iodo-4-methylphenyl)-2-oxoacetate (248.5 mg, 35%) as a yellowish oil.
Physical and spectroscopic data of compound i: Mp 86−88 ºC (crystallized from hexane); IR (NaCl) νmax (cm − 1 ) 2954w, 2925w, 1734m, 1680s, 1585m, 1547m, 1429m, 1320m, 1203s, 922s, 912m, 735m; 
(E)-Methyl 2-(4-iodo-2-methylphenyl)-2-(methoxyimino)acetate (ii).
A suspension of keto-ester i (202.4 mg, 0.666 mmol) and N-methylhydroxylamine hydrochloride (240 mg, 2.87 mmol) in anhydrous pyridine (3.5 mL) was stirred at room temperature under nitrogen overnight. Work up as usual followed by purification by column chromatography with hexane-Et2O (from 8:2 to 6:4) as eluent afforded methoxyimino derivative ii (157.2 mg, 71%) as a white solid. Mp 50−52 ºC (crystallized from hexane); IR (KBr) νmax (cm − 1 ) 2940w, 2886w, 1725s, 1597w, 1437m, 1323m, 1219s, 1066s, 1018s, 957m, 846m, 780m ; 1 H-NMR (300 MHz) δ (ppm) 7.63 (1H, br s, H-3), 7.57 (1H, dd, J = 8.1, 1. 4 Hz, 1725s, 1600m, 1588m, 1494s, 1454m, 1437m, 1323m, 1240s, 1222s, 1191w, 1121m, 1065s, 1018s, 956w, 787w 2939m, 2258w, 1728s, 1603m, 1494s, 1458m, 1437m, 1312m, 1239s, 1149s, 1069s, 1020s, 952m, 912m, 835m, 785m, 733s ; 1 H NMR (300 MHz) δ 7.59 (1H, d, J = 1.6 Hz, H-2'), 7.40 (1H, dd, J = 7.9, 1.6 Hz, H-6'), 7.14 (1H, m, H-3'' partially overlapped with the signals of H-5' and H-5''), 7.13 (1H, m, H-5' partially overlapped with the signals of H-3'' and H-5''), 7.10 (1H, m, H-5''partially overlapped with the signals of H-5' and H-3''), 6.86 (1H, ddd, J = 7.4, 7.3, 0.8 Hz, 2936m, 2859m, 1727s, 1602w, 1495m, 1460m, 1438m, 1366m, 1311m, 1243s, 1214s, 1156s, 1067s, 1020m, 955w, 847w, 752m ; 1 H NMR (300 MHz) δ 7.38 (1H, s, H-2'), 7.19 (1H, dd, J = 7.8, 1.6
Hz, H-6'), 7.14 (1H, 
(E)-6-(4-(2-Methoxy-1-(methoxyimino)-2-oxoethyl)-3-((o-tolyloxy)methyl)phenyl)hexanoic acid (Hapten KMa):
IR (NaCl) νmax (cm -1 ) 3293w (br), 2937m, 2858w, 1725s, 1708s, 1601w, 1494m, 1460w, 1438m, 1310m, 1242s, 1190w, 1122m, 1067s, 1019s, 953w, 782w, 752m; 1 H NMR (300 MHz) δ 7.38 (1H, s, H-2'), 7.20 (1H, dd, J = 7.9, 1.5 Hz, H-6'), 7.14 (1H, (7) 
(E)-Methyl 2-(2-((4-iodo-2-methylphenoxy)methyl)phenyl)-2-(methoxyimino)acetate

(E)-tert-Butyl 6-(4-((2-(2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)-3-methylphenyl)hex-5-ynoate (8):
IR (NaCl) νmax (cm -1 ) 2977w, 2939w; 1727s, 1604w, 1500m, 1461w, 1437w, 1367w, 1313w, 1262w, 1233m, 1147m, 1132m, 1069m, 1019m, 958w, 758w, 738w ; 1 H NMR (300 MHz) δ 7.54 (1H, dd, J = 7.3, 1.5 Hz, H-3''), 2937s, 2856m, 2660m, 1727s, 1708s, 1609w, 1503s, 1437m, 1380w, 1317m, 1251s, 1220s, 1132m, 1070s, 1046w, 1019s, 938m, 788w 
(E)-6-(4-((2-(2-Methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)-3-methylphenyl)hexanoic acid (Hapten
KMb). IR (NaCl) νmax (cm -1 ) 3325w (broad),
(E)-tert-Butyl 6-(2-((2-(2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)phenyl)hex-5-ynoate (13): IR
(NaCl) νmax (cm -1 ) 2975w, 2934w, 1735s, 1488w, 1441w, 1369w, 1307w, 1214m, 1137s, 1064m, 1013m, 961w, 754m ; 1 H NMR (300 MHz) δ 7.69 (1H, dd, J = 7.7, 0.7 Hz, H-3''), 7.44 (1H, ddd, J = 7.7, 7.6, 1. 4 Hz, m, m, , 6.87 (1H, ddd, J = 7.5, 7.5, 0.7 Hz, H-4'), 
(E)-tert-Butyl 6-(2-((2-(2-methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)phenyl)hexanoate (14): IR (NaCl)
νmax (cm -1 ) 2967w, 2936m, 2862w, 1727s, 1594w, 1492w, 1450m, 1366w, 1318m, 1224s, 1156s, 1068s, 1019s, 955w, 752m ; 1 H NMR (300 MHz) δ 7.57 (1H, dd, J = 7.6, 1.4 Hz, H-3''), 7.45 (1H, ddd, J = 7.6, 7.6, 1.5 Hz, H-4''), 7.38 (1H, ddd, J = 7.6, 7.5, 1. 4 2938m, 2868w, 1726s, 1602w, 1586w, 1494m, 1459m, 1367m, 1313m, 1214s, 1194m, 1151s, 1123m, 1068s, 1013m, 953w, 847w, 752m ; 1 H NMR (300 MHz) δ 7.57 (1H, d, J = 7.5 Hz, H-6'), 7.44 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-5'), 7.37 (1H, ddd, J = 7.5, 7.5, 1. 2940m, 2804w, 1709s, 1601w, 1592w, 1494m, 1462m, 1388w, 1312m, 1240s, 1195m, 1123m, 1069s, 1012m, 953w, 753m ; 1 H NMR (300 MHz) δ 7.57 (1H, d, J = 7.5 Hz, H-6'), 7.44 (1H, ddd, J = 7.5, 7.5, 1.6 Hz, H-5'), 7.38 (1H, ddd, J = 7.5, 7.5, 1. 4 Hz, 7.20 (1H, dd, J = 7.5, 1.6 Hz, 7.13 (1H, m, partially overlapped with the signal of H-5''), 7.10 (1H, m, H-5'' partially overlapped with the signal of H-3''), 6.85 (1H, ddd, J = 7.5, 7.4, 0.8 Hz, 6.76 (1H, d, J = 8.1 Hz, 4.96 (2H, s, OCH2), 4.21 (2H, t, J = 6.7 Hz, H-6), 4.03 (3H, s, NOCH3), 2.29 (2H, t, J = 7. 
(E)-6-(2-((2-(2-Methoxy-1-(methoxyimino)-2-oxoethyl)benzyl)oxy)phenyl)hexanoic acid (Hapten
(E)-tert-Butyl 6-(2-(methoxyimino)-2-(2-((o-tolyloxy)methyl)phenyl)acetoxy)hexanoate (17): IR (NaCl) νmax (cm -1 ) 2969m,
(E)-6-(2-(Methoxyimino)-2-(2-((o-tolyloxy)methyl)phenyl)acetoxy)hexanoic acid (Hapten
KMe): IR (NaCl) νmax (cm -1 ) 3329m (broad),
(E)-tert-Butyl 6-(((2-methoxy-2-oxo-1-(2-((o-tolyloxy)methyl)phenyl)ethylidene)amino)oxy)hexanoate (19): IR
(NaCl) νmax (cm -1 ) 2974w, 2935w, 1727s, 1602w, 1494w, 1460w, 1437w, 1367w, 1321w, 1241m, 1219m, 1152m, 1123s, 1068m, 1001m, 914w, 753m, 732m (E) methyl)phenyl)ethylidene)amino)oxy)hexanoic acid (Hapten KMo): 3026m, 2948m, 2853m, 1733s, 1708s, 1602w, 1590w, 1495s, 1437m, 1310m, 1241s, 1215s, 1123m, 1069s, 1001s, 781d,754s ; 1 H NMR (300 MHz) δ 7.57 (1H, d, J = 7.5 Hz, H-6'), 7.44 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-5'), 7.37 (1H, ddd, J = 7.5, 7.5, 1. 4 Hz, a Values are the mean of three independent determinations and correspond to an inhibition curve with an Amax value between 0.8 and 1.5. b OVA conjugate concentration was either 100 or 1000 ng mL −1 . c Amax values were lower than 0.8 at 300 ng mL −1 mAb concentration and the highest coating concentration.
Assay protocol
Microplates were coated by overnight incubation with 100 µL per well of OVA conjugate solution in CB. All incubation steps were performed at room temperature with sealed plates, and after each step, microwells were washed four times with washing solution. The competitive step was carried out during 1 h with 50 µL per well of analyte solution in PBS plus 50 µL per well of antibody dilution in PBST. Retained antibodies were amplified by incubation during 1 h with 100 µL per well of rabbit anti-mouse immunoglobulins polyclonal antibody-peroxidase conjugate diluted 1/2000 in PBST. Signal was produced with 100 µL per well of freshly prepared enzyme substrate solution.
After 10 min at room temperature, enzyme activity was stopped upon adding 100 µL per well of 2.5 M sulfuric acid. Absorbances were immediately read at 492 nm with a reference wavelength at 650 nm. 
